Fibronectin type III domain-containing protein 7 (FNDC7)

Fibronectin type III domain-containing protein 7 (FNDC7) is a member of the fibronectin type III domain-containing (FNDC) protein family, distinguished by the presence of at least one fibronectin type III domain found in extracellular matrix proteins[1][2]. FNDC7 is predicted to be located in the extracellular region, and functional genomics studies indicate that it may participate in cellular processes such as tissue development, adhesion, migration, and proliferation—functions typical of the broader FNDC family, though the specific role of FNDC7 remains poorly characterized in the literature[2][1]. Alterations in FNDC7 expression or methylation have been observed in disease contexts, such as differential mRNA expression in certain cancers (often downregulated in tumors compared to normal tissue) and as an epigenetic marker of tobacco exposure in Native Hawaiian smokers, potentially modifying cancer risk[1][2]. Prognostic studies implicate FNDC7 as a possible biomarker in cancers like colorectal cancer, where higher expression has been associated with favorable survival outcomes[2]. There are currently no known drugs directly targeting FNDC7, and its utility as a therapeutic target or clinically validated biomarker remains to be established. No notable safety concerns or therapeutic challenges are documented for FNDC7 as a target, likely due to the absence of direct pharmacological interventions.

Other names

Fibronectin type III domain-containing protein 7FNDC7FLJ35838